CoChat

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). We report on the primary outcome of objective response rate (ORR) and secondary endpoints of toxicity, clinical benefit, progression-free survival, overall survival, and durations of response/treatment. In 84 patients in 9 histotype cohorts, all patients experienced ≥1 adverse event and treatment-related adverse event; 1 death was possibly treatment-related. ORR was highest in angiosarcoma (3/8) and undifferentiated pleomorphic sarcoma (2/10), meeting predefined endpoints. Results of our exploratory investigation of predictive biomarkers show: CD8 + T cell infiltrates and PD-1 expression correlate with improved ORR; upregulation of immune-related pathways correlate with improved efficacy; Hedgehog pathway expression correlate with resistance. Exploration of this combination in selected sarcomas, and of Hedgehog signaling as a predictive biomarker, warrants further study in larger cohorts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-30874-8

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Response to the combination of nivolumab and bempegaldesleukin in patients with metastatic sarcoma. A CONSORT diagram. B Waterfall plot of overall best response (% change in sum of length measurements) of target lesions/nodes (RECIST v1.1; n = 77 patients evaluable for efficacy). Horizontal line represent cutoff for partial response (PR). Dot indicates achievement of response according to radiographic assessments despite classification as PD in non-target lesions (per RECIST v1.1). Two patients with progressive disease had target lesions that were not evaluable by RECIST. C Progression-free survival (PFS) for each patient (n = 77 patients). PFS is listed for patients without progression longer than 1 year and for patients who did not yet reach progression (indicated by + ). Dashed line indicates 24 weeks. ASPS alveolar soft part sarcoma, UPS undifferentiated pleomorphic sarcoma, MFS myxofibrosarcoma. Source data are provided as a Source Data file.
Fig. 1 Response to the combination of nivolumab and bempegaldesleukin in patients with metastatic sarcoma. A CONSORT diagram. B Waterfall plot of overall best response (% change in sum of length measurements) of target lesions/nodes (RECIST v1.1; n = 77 patients evaluable for efficacy). Horizontal line represent cutoff for partial response (PR). Dot indicates achievement of response according to radiographic assessments despite classification as PD in non-target lesions (per RECIST v1.1). Two patients with progressive disease had target lesions that were not evaluable by RECIST. C Progression-free survival (PFS) for each patient (n = 77 patients). PFS is listed for patients without progression longer than 1 year and for patients who did not yet reach progression (indicated by + ). Dashed line indicates 24 weeks. ASPS alveolar soft part sarcoma, UPS undifferentiated pleomorphic sarcoma, MFS myxofibrosarcoma. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Immune cell content in on-treatment samples differentiates response. A–C Percent (A) PD-1-positive cells (Baseline n = 5 patients [PR], 12 [SD], 31 [PD]; On-Treatment n = 3 [PR], 7 [SD], 23 [PD]), (B) CD8-positive T cells (Baseline n = 4 patients [PR], 11 [SD], 32 [PD]; On-Treatment n = 3 [PR], 7 [SD], 22 [PD]), (C) change in PD-1-positive cells (n = 2 patients [PR], 6 [SD], 20 [PD]), as determined by IHC and categorized by best response and sample time point. A–C Colors indicate trial cohort. ASPS alveolar soft part sarcoma, UPS undifferentiated pleomorphic sarcoma, MFS myxofibrosarcoma. P values are nominal and derived from linear model of positive cells with ORR including sarcoma subtype as a covariate. Boxplot shows the median with hinges at 25th and 75th percentile with whiskers extending to smallest or largest value, no more than 1.5 times interquartile range from the hinges. All values are shown with points. D, F Immune markers in baseline (n = 41 patients) and on-treatment samples (n = 38 patients), respectively, clustered using Manhattan distance and Ward D clustering on the immune populations from RNA-seq (bottom heatmap), with color coding for best response (top row), quartile of percent positive cells for 5 immune markers as detected using IHC, and immune clusters according to the dendrogram. E, G Kaplan–Meier plot of progression-free survival of 3 and 2 immune clusters defined in D and F, respectively. Logrank p values shown for significant comparisons (Baseline n = 8 patients [A], 6 patients [B], n = 27 [C], On-Treatment n = 9 patients [A], On-Treatment n = 29 [C]). Source data are provided as a Source Data file.
Fig. 2 Immune cell content in on-treatment samples differentiates response. A–C Percent (A) PD-1-positive cells (Baseline n = 5 patients [PR], 12 [SD], 31 [PD]; On-Treatment n = 3 [PR], 7 [SD], 23 [PD]), (B) CD8-positive T cells (Baseline n = 4 patients [PR], 11 [SD], 32 [PD]; On-Treatment n = 3 [PR], 7 [SD], 22 [PD]), (C) change in PD-1-positive cells (n = 2 patients [PR], 6 [SD], 20 [PD]), as determined by IHC and categorized by best response and sample time point. A–C Colors indicate trial cohort. ASPS alveolar soft part sarcoma, UPS undifferentiated pleomorphic sarcoma, MFS myxofibrosarcoma. P values are nominal and derived from linear model of positive cells with ORR including sarcoma subtype as a covariate. Boxplot shows the median with hinges at 25th and 75th percentile with whiskers extending to smallest or largest value, no more than 1.5 times interquartile range from the hinges. All values are shown with points. D, F Immune markers in baseline (n = 41 patients) and on-treatment samples (n = 38 patients), respectively, clustered using Manhattan distance and Ward D clustering on the immune populations from RNA-seq (bottom heatmap), with color coding for best response (top row), quartile of percent positive cells for 5 immune markers as detected using IHC, and immune clusters according to the dendrogram. E, G Kaplan–Meier plot of progression-free survival of 3 and 2 immune clusters defined in D and F, respectively. Logrank p values shown for significant comparisons (Baseline n = 8 patients [A], 6 patients [B], n = 27 [C], On-Treatment n = 9 patients [A], On-Treatment n = 29 [C]). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Differentially expressed pathways in partial responders. A Volcano plot of differential expression between partial responders (n = 7 patients) and non-responders (n = 41 patients). Model included trial cohort, patient, purity, and sample time point as covariates. Points represent genes. Genes in Hallmark hedgehog pathway are highlighted in red. B Top 10 upregulated and all 5 downregulated Hallmark pathways between partial responders (n = 7 patients) and non-responders (n = 41 patients). Analysis performed using fgsea in R. All pathways are significantly enriched (BH adjusted p < 0.05). C Heatmap of ssGSEA scores of baseline (n = 41 patients) and on-treatment (n = 38 patients) expression in individual patients for top enriched pathways in (B) using the leading-edge genes from the fgsea analysis. D, E. Kaplan–Meier plot of progression-free survival of patients divided into four groups depending on the amount CD8 + T cells and ssGSEA score of hedgehog pathway enrichment across cohort (high versus low, split by median). Scores derived from expression at baseline in (D) and on-treatment samples in (E). Note, cross-validation analysis does not output p values. Source data are provided as a Source Data file.
Fig. 3 Differentially expressed pathways in partial responders. A Volcano plot of differential expression between partial responders (n = 7 patients) and non-responders (n = 41 patients). Model included trial cohort, patient, purity, and sample time point as covariates. Points represent genes. Genes in Hallmark hedgehog pathway are highlighted in red. B Top 10 upregulated and all 5 downregulated Hallmark pathways between partial responders (n = 7 patients) and non-responders (n = 41 patients). Analysis performed using fgsea in R. All pathways are significantly enriched (BH adjusted p < 0.05). C Heatmap of ssGSEA scores of baseline (n = 41 patients) and on-treatment (n = 38 patients) expression in individual patients for top enriched pathways in (B) using the leading-edge genes from the fgsea analysis. D, E. Kaplan–Meier plot of progression-free survival of patients divided into four groups depending on the amount CD8 + T cells and ssGSEA score of hedgehog pathway enrichment across cohort (high versus low, split by median). Scores derived from expression at baseline in (D) and on-treatment samples in (E). Note, cross-validation analysis does not output p values. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv: Genomics (2013).

Cited by

See all 65

Metadata

Authors
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., Rosenbaum, E., Chi, P., Nacev, B., Chan, J. E., Slotkin, E. K., Kiesler, H., Adamson, T., Ling, L., Rao, P., Patel, S., Livingston, J. A., Singer, S., Agaram, N. P., Antonescu, C. R., Koff, A., Erinjeri, J. P., Hwang, S., Qin, L.-X., Donoghue, M. T. A., & Tap, W. D.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
D’Angelo, Sandra P.
Venue
Nature Communications
Published
2022-06-16
Volume
13
Issue
1
Pages
3477-3477
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4283029304
Cited by
60
References
69
Citations by year
2026: 10 · 2025: 15 · 2024: 17 · 2023: 15 · 2022: 3
FWCI
5.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Nektar Therapeutics
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
nivolumab, metastatic sarcoma, anti-PD-1 therapy, CD122, combination immunotherapy, objective response rate, angiosarcoma, malignant fibrous histiocytoma, CD8+ T cell infiltration, PD-1 expression, Hedgehog signaling, predictive biomarkers, treatment-related adverse events
MeSH terms
Antineoplastic Agents, Immunological, Nivolumab, Humans, Interleukin-2, Pilot Projects, Sarcoma, Neoplasms, Second Primary, Hedgehog Proteins, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. https://app.cochat.ai/papers/10.1038/s41467-022-30874-8
The paper
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., Rosenbaum, E., Chi, P., Nacev, B., Chan, J. E., Slotkin, E. K., Kiesler, H., Adamson, T., Ling, L., Rao, P., . . . Tap, W. D. (2022). Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nature Communications. https://doi.org/10.1038/s41467-022-30874-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.